Proactive Investors - Run By Investors For Investors

Ebiquity slides as it warns on flat profits for continuing business in 2019

The marketing and media consultancy said contractual obligations relating to the sale of its Advertising Intelligence business meant profitability would be "at a similar level to the year just ended”
Adverts
The firm sold its Advertising Intelligence arm to Nielsen Media Research in early January

Ebiquity plc (LON:EBQ) shares dropped in early trading Tuesday after the firm forecast flat profits from its continuing business in the new financial year.

In an update for the fiscal year ended 31 December 2018, the marketing and media consultancy said trading had been in line with expectations, adding that its year-end net debt of £28mln had been reduced by around £20mln post-period end after the sale of its advertising intelligence business to Nielsen Media Research Limited on 2 January 2019.

READ: Marketing group Ebiquity plummets as it warns on profits

Following the disposal, Ebiquity said it was targeting an 8% growth rate for its continuing consultancy business in 2019, similar to that of the prior year, however its cost base would continue to reflect the need to fulfil contractual obligations of providing support services to Nielsen in relation to the disposed business, and as such it expected profitability for the consultancy business to “remain at a similar level to the year just ended”.

Michael Karg, chief executive of Ebiquity, said the management team at the firm was now focused on “seizing the significant market opportunities as well as on aligning our business following the divestiture”.

Shares were down 8.2% at 56p.

View full EBQ profile View Profile

Ebiquity PLC Timeline

Article
February 13 2018

Related Articles

clapperboard
December 19 2018
Interim profits showed a modest recovery with the number of contracts signed rising to 77 from 74 a year earlier
ipad
September 19 2018
“Cello Health is successfully building its early stage asset development advisory platform for biotech clients, as well as growing its core later stage and post-launch franchise with pharmaceutical clients”
marketing
January 29 2019
“With the geopolitical landscape remaining in flux, clients are looking for greater certainty from their marketing programmes which our agencies and data businesses are proving able to provide"

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use